NOV 15, 2020 8:15 AM PST

Antidepressant May Prevent Worsening of COVID-19 Infections

WRITTEN BY: Annie Lennon

 

Researchers from the Washington University School of Medicine in St. Louis have found that fluvoxamine, a common antidepressant used to treat Obsessive-Compulsive Disorder (OCD), may prevent the degradation of COVID-19 cases in those who have recently been infected. 

The researchers were inspired to conduct the study following findings from last year that fluvoxamine is able to prevent a deadly immune response called sepsis. As negative outcomes from COVID-19 seem to occur from an overproduction of immune cells known as cytokines, the researchers thought that the drug might also be able to treat those infected with the virus. 

As such, they launched a randomized, double-blind trial to investigate the effects of fluvoxamine alongside a placebo in 152 adult outpatients infected with COVID-19. In doing so, they found that none of the participants on fluvoxamine saw clinical deterioration within 15 days, whereas six patients on the placebo did. Of these six people, four were hospitalized for between four and 21 days, with one being put on a ventilator for ten days. 

“The patients who took fluvoxamine did not develop serious breathing difficulties or require hospitalization for problems with lung function,” says Eric J. Lenze, MD, one of the researchers behind the study. 

“Most investigational treatments for COVID-19 have been aimed at the very sickest patients, but it’s also important to find therapies that prevent patients from getting sick enough to require supplemental oxygen or to have to go to the hospital. Our study suggests fluvoxamine may help fill that niche.”

The researchers say that while there are multiple ways in which the drug may have helped patients infected with COVID-19, they suspect it chiefly works by interacting with the sigma-1 receptor to reduce the production of inflammatory molecules. This would match previous research showing that fluvoxamine reduces inflammation in animals with sepsis. 

While interesting results, the researchers warn that there are some limitations to their findings. In particular, they say that their study sample size was small. As such, they now aim to launch a larger trial to test the drug in the coming weeks. 

 

Sources: Neuroscience NewsJAMA Network

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
SEP 20, 2021
Microbiology
Antibiotics and Viruses Team Up to Kill Drug-Resistant Bugs
SEP 20, 2021
Antibiotics and Viruses Team Up to Kill Drug-Resistant Bugs
Before antibiotics became a common treatment for infections, researchers considered using viruses that infect bacteria, ...
OCT 12, 2021
Drug Discovery & Development
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
OCT 12, 2021
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
Researchers at Japan’s Osaka University recently developed and tested a novel vaccine that may protect a ...
OCT 15, 2021
Drug Discovery & Development
Oxytocin Therapy Shows No Benefit for Autistic Children
OCT 15, 2021
Oxytocin Therapy Shows No Benefit for Autistic Children
Intranasal oxytocin therapy does not benefit autistic children and adolescents. The corresponding study was published in ...
NOV 08, 2021
Coronavirus
Pfizer Claims Their New COVID-19 Pill Reduces Hospitalization Risk by 89%
NOV 08, 2021
Pfizer Claims Their New COVID-19 Pill Reduces Hospitalization Risk by 89%
Current treatments for COVID-19 have to be administered intravenously, so a pill that could treat patients would be huge ...
NOV 19, 2021
Health & Medicine
Increase in Cannabis Use Disorder in Prenatal Hospitalizations
NOV 19, 2021
Increase in Cannabis Use Disorder in Prenatal Hospitalizations
A recent study by Columbia University and Weill Cornell Medicine researchers found that cannabis use disorder (CUD) in p ...
NOV 22, 2021
Microbiology
Researchers Solve the Structure of the HIV Capsid, May Be a New Drug Target
NOV 22, 2021
Researchers Solve the Structure of the HIV Capsid, May Be a New Drug Target
Though treatments are available, there is no cure or vaccine from HIV, which impacts about 38 million people worldwide. ...
Loading Comments...